Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III OH2 versus investigator-selected salvage chemotherapy or best supportive care in previously treated unresectable or metastatic melanoma
CTR20223472Phase 3Active
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of OH2 in melanoma, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Mar 2023; status: active.
02
Drugs
OH2
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20223472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223472.